HLA class II-melanoma peptide complex (HLA-II/Melanoma complex)

The HLA class II-melanoma peptide complex is a specialized immunological target consisting of Major Histocompatibility Complex (MHC) class II molecules (such as HLA-DR, HLA-DQ, or HLA-DP) bound to helper peptides derived from melanoma-associated antigens. These antigens typically include proteins like MAGE-A3, tyrosinase, gp100, and NY-ESO-1, which are overexpressed in melanoma cells [1][2]. The primary biological role of this complex is to present these tumor-derived fragments to CD4+ T helper cells, which are essential for orchestrating a comprehensive anti-tumor immune response [3]. In many melanoma patients, the natural presentation of these peptides is insufficient to trigger an effective immune clearance, leading to tumor progression. Therapeutic interventions, including peptide-based vaccines and engineered T-cell receptor (TCR) therapies, aim to enhance the visibility of these complexes to the immune system [4]. By successfully targeting this complex, clinicians hope to stimulate the production of pro-inflammatory cytokines and provide the necessary 'help' to cytotoxic CD8+ T cells to effectively destroy melanoma tissue [5]. Sources: [1] UniProt (P01903, P01911); [2] PubMed (PMID: 8144860); [3] Cancer Immunology Research (MHC II in Melanoma); [4] ClinicalTrials.gov (NCT00001564); [5] Journal of Experimental Medicine (Topalian et al.).

Other names

MHC class II-melanoma antigen complexHLA-DR-melanoma peptide complexMelanoma-associated helper peptide-MHC II complexHLA-DQ-melanoma peptide complexHLA-DP-melanoma peptide complex

Therapeutic agents, such as peptide vaccines, provide specific melanoma-derived antigens that are processed and loaded onto HLA class II molecules. These complexes are then presented on the surface of antigen-presenting cells or tumor cells to CD4+ T helper cells. The recognition of these complexes by T-cell receptors (TCRs) triggers the activation of helper T cells, which secrete cytokines (e.g., IFN-gamma, IL-2) to enhance the recruitment and cytotoxic activity of CD8+ T cells and B cells against the tumor.